|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J Thorac Cardiovasc Surg 2007;134:267-268
© 2007 The American Association for Thoracic Surgery
Letter to the Editor |
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research, Seoul, South Korea
We appreciate the constructive comments by Dr Augoustides regarding our study.1
He raised the issue of whether hyperoxia, which is a potent pulmonary vasodilator, was adequately controlled between the control and sildenafil groups in our study. The arterial oxygen tension (PaO2) levels were 271 ± 89 mm Hg versus 254 ± 108 mm Hg (P = .602) before the first hemodynamic measurement and 276 ± 48 mm Hg versus 235 ± 55 mm Hg (P = .03) immediately after the last measurement with 60% oxygen in the control and sildenafil groups, respectively. There were no significant changes in the PaO2 values within each group.
Hypoxic pulmonary vasoconstriction has been well studied for decades, with the stimulus identified as both mixed venous and alveolar oxygen tension in small arteries and systemic PaO2 in large pulmonary vessels.2
However, no comprehensive data exist regarding graded response of the pulmonary vasculature to changes in PaO2 above 120 mm Hg (hyperoxia), especially in patients with long-standing valvular heart disease with concomitant pulmonary hypertension, as in our study. In an animal study, Rudolph and Yuan3
studied the relationship between PaO2 and pulmonary vascular resistance and demonstrated that there is no further decrease in pulmonary vascular resistance above the PaO2 of 50 to 60 mm Hg. Therefore, although the PaO2 was lower in the sildenafil group after the last measurement, this should not have any further clinically significant effects on the pulmonary vascular resistance.
We agree with Augoustides that proper control of PaO2 between the groups should be mentioned to clarify any confounding factors.
We also agree that further studies with an intravenous form of sildenafil, which is currently not available in our country, should be performed, especially with regard to the period of weaning from cardiopulmonary bypass, and we hope that our study will draw much attention and further clinical research in this area.
References
Related Article
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |